Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

The share price of Danish pharmaceutical giant Novo Nordisk ( NVO +1.31%) hit a four-year low Monday, falling below $44 a ...

Septerna, Inc. (SEPN) shares soared 7% in the last trading session to close at $22.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

Novo Nordisk NVO shares have climbed 10% in the past month, supported by a mix of certain internal factors and positive market catalysts, which boosted investor confidence. In early September, Novo ...

Novo Nordisk, the 102-year-old Danish drugmaker behind the blockbuster drugs Ozempic and Wegovy, is laying off thousands of workers as it seeks to recoup some of the revenue it’s lost to competitors ...

The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans ...